Physician profile
Robert K Aki
NPI 1710083944
$5,634.94
in general payments reported to CMS, 2019-2025
19 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $524 · 2021: $447 · 2022: $808 · 2023: $1,168 · 2024: $1,227 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784 · Long Term Medical Supply Or Device Loan: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.95 |
| Long Term Medical Supply Or Device Loan | $329.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,534.52 | 2021-2025 | Dalvance, Teflaro |
| Horizon Therapeutics Plc | $718.17 | 2019-2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $525.86 | 2022-2023 | Seglentis |
| Allergan, INC. | $516.51 | 2019-2020 | |
| Bioventus LLC | $514.47 | 2019-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System, Durolane |
| Smith+Nephew, INC. | $378.64 | 2019-2020 | |
| Integra Lifesciences Corporation | $329.38 | 2024 | Integra |
| Amgen INC. | $280.42 | 2024-2025 | Krystexxa |
| Melinta Therapeutics, LLC | $276.05 | 2022-2024 | Kimyrsa, Orbactiv |
| Averitas Pharma INC. | $267.66 | 2024-2025 | Qutenza |
| Medtronic, INC. | $61.81 | 2024 | Intellis Adaptivestim |
| Dynasplint Systems INC. | $44.73 | 2025 | Dynasplint |
| Organogenesis INC. | $37.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $36.86 | 2022-2023 | Nuzyra |
| Bone Support INC. | $32.62 | 2024 | Ceramentbone Void Filler, Cerament G |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.18 | 2019 | |
| Sandoz INC. | $24.32 | 2019 | |
| Novo Nordisk INC | $16.31 | 2020 | |
| Abbott Laboratories | $13.48 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.